Merck 'bio-inks' deal to use Organovo's 3D printed liver for preclinical studies

By Dan Stanton contact

- Last updated on GMT

Merck & Co. (MSD) is set to use Organovo's 3D printed human liver tissue in preclinical studies
Merck & Co. (MSD) is set to use Organovo's 3D printed human liver tissue in preclinical studies

Related tags: Liver

Merck & Co. has struck a deal with Organovo to use a 3D printed human liver system for toxicology testing as a supplement to in vitro and preclinical animal testing.

San Diego, California-based research services firm Organova launched its first product last November, the exVive3D Human Liver Tissue for use in toxicology and other preclinical drug testing.

The system comprises of living human tissues created through the firm’s 3D bioprinting process, and in an SEC filing this week the firm said it had entered into a multi-year research collaboration agreement with Merck & Co. (known as MSD outside North America).

“The Agreement will give Merck access to Organovo’s commercial exVive3D Human Liver Tissue service,”​ the filing said, “and will also involve a collaboration to develop multiple custom tissue models utilizing the Company’s proprietary NovoGen Bioprinting Platform, for use in drug development”

Further details of the deal have not been disclosed but Organovo’s share price shot up more than 18% following the announcement.

The liver model is made from primary hepatocytes, endothelial cells, and hepatic stellates which are expanded and prepared into a ‘printable bioink. After being loaded onto a bioprinter and printed in a precise orientation, the tissues are conditioned into models with precise and reproducible architecture that can remain fully functional and stable for greater than 40 days.

According to the firm, the exVive3D system can provide human-specific data to aid in the prediction of liver tissue toxicity or ADME in the preclinical stage of drug development, and offers a number of advantages over cultured bacteria or mammalian cells used for in vitro​ profiling.

“The tissue provides the ability to measure analytical protein, gene expression, histologic, toxicological and metabolic endpoints with greater physiological relevance than traditional cell and tissue models over an extended in vitro lifespan,”​ Executive Vice President Michael Renard told this publication​ last year.

Organovo also announced its end of fiscal year 2015 earnings this week, with net revenues of around $571,000 for the year. However, following the launch of exVive3D, CFO Barry Michaels was optimistic about 2016.

“We expect to gain greater adoption from the global pharmaceutical community and look forward to partnering with them in the discovery and development of their products,”​ he said. “We enter fiscal 2016 with confidence and momentum and look forward to continued expansion of our platform technology across multiple industries utilizing various fully cellular tissues.”

Related news

Show more

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q² Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Related suppliers

Follow us

Products

View more

Webinars